Save time and get answers to complex questions with AI chat
Motegrity ingredients?What is dabrafenib mesylate msn patent issue?How many years does kadcyla's market exclusivity last?What excipients are combined with ruxolitinib in apotex's medication?Patent tenofovir alafenamide gilead?
Tigecycline is often less effective against bacteria that already have established resistance mechanisms, especially those that lower drug accumulation or actively pump tetracycline-like compounds out of the cell. Commonly encountered resistant organisms include: - Enterococcus faecalis and Enterococcus faecium that carry resistance determinants making tetracycline-class activity unreliable. - Pseudomonas aeruginosa - Proteus species - Klebsiella pneumoniae - Enterobacter species - Acinetobacter baumannii
Clinically important tigecycline resistance is commonly linked to: - Efflux pumps that export tetracycline-related drugs. - Ribosomal protection proteins (tetracycline-class resistance) that reduce tigecycline binding or action at the ribosome. - Target or permeability changes that lower intracellular tigecycline concentration. These mechanisms help explain why many gram-negative pathogens with robust resistance systems can show reduced susceptibility to tigecycline.
Hospitals typically rely on susceptibility testing (reported as tigecycline MIC/interpretation) from the lab for the specific isolate rather than assuming susceptibility by species alone, since resistance can vary widely within the same species and even between strains.
Some organisms show variable tigecycline activity depending on local resistance genes and prior antibiotic pressure. That variability is exactly why susceptibility testing matters—two isolates of the same species can differ in tigecycline susceptibility. If you tell me the species (or gram-positive vs gram-negative) you’re focused on, I can narrow this to the most relevant resistant groups for that organism.
Other Questions About Common :